Trial Profile

A Pivotal Clinical Study to Evaluate Evenamide in Treatment Resistant Schizophrenia Patients not Responding to Clozapine

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 19 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evenamide (Primary)
Indications Schizophrenia
Focus Registrational; Therapeutic Use
Sponsors Newron Pharmaceuticals

Most Recent Events

09 Jan 2025 According to a Newron Pharmaceuticals media release, the company expects to begin pivotal Phase III trial in H1 2025.
07 Jun 2022 According to a Newron Pharmaceuticals media release, the company expects to initiate this potentially pivotal study in the first quarter of 2023.
09 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com